OTLK FY2026 EPS Raised by Brookline Capital Management

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Analysts at Brookline Capital Management increased their FY2026 EPS estimates for Outlook Therapeutics in a note issued to investors on Monday, December 30th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings per share of $0.65 for the year, up from their prior estimate of $0.61. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($3.84) per share.

Outlook Therapeutics (NASDAQ:OTLK) last issued its quarterly earnings results on Friday, December 27th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.06.

Several other equities analysts have also commented on OTLK. Ascendiant Capital Markets lowered their target price on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. BTIG Research reduced their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a report on Friday, November 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, November 29th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Outlook Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $32.73.

Outlook Therapeutics Price Performance

Shares of OTLK opened at $1.86 on Tuesday. The stock has a market capitalization of $44.00 million, a PE ratio of -0.17 and a beta of 0.46. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85. The business’s fifty day moving average price is $3.73 and its 200 day moving average price is $5.84.

Institutional Trading of Outlook Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of OTLK. Great Point Partners LLC raised its position in Outlook Therapeutics by 15.0% in the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after acquiring an additional 221,510 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Outlook Therapeutics in the 2nd quarter worth approximately $232,000. AQR Capital Management LLC bought a new stake in shares of Outlook Therapeutics in the 2nd quarter worth approximately $75,000. Susquehanna Fundamental Investments LLC acquired a new stake in Outlook Therapeutics during the second quarter valued at approximately $303,000. Finally, Christensen King & Associates Investment Services Inc. bought a new stake in Outlook Therapeutics during the third quarter worth approximately $55,000. Institutional investors own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.